afaxys.comAfaxys, Inc.

we are afaxys We're on a mission to deliver products and services to healthcare providers affordably, reliably, and with an unwavering focus on customer service and stakeholder needs. learn more at afaxys pharma we are the experts in emergency contraceptives For more information on our range of emergency contraceptive products: click here -- -- -- -- introducing -- -- the abc alliance -- For more information on the ABC Alliance or to join Afaxys Group Services to receive better access to affordable IUDs: -- click here -- -- -- -- Afaxys Pharma provides reliable, affordable access to healthcare products for the public healthcare sector. HEALTHCARE PROVIDERS Afaxys Pharma brings a strong portfolio of branded and generic oral contraceptives to the public health market. We are dedicated to offering a sustainable supply of quality, affordable women's healthcare products and services for the public health sector. Read More Products Our core product line offers reliable, consistent, and affordable access to quality women's healthcare options to public health professionals and their patients. Read More Afaxys Group Services connects its members to suppliers who provide mission-critical products and services. Services/ Offerings Afaxys Group Services negotiates favorable pricing across a broad base of healthcare products and services so its members have access to best-in-class suppliers and service providers. Our strategic sourcing business model enables Afaxys to secure and provide consistent and reliable access to quality products and services at an affordable price. Read More Our Products Afaxys Pharma offers a broad range of contraceptive options. EContra One-Step ® (Levonorgestrel) Tablet, 1.5 mg EContra One-Step ® (Levonorgestrel) Tablet, 1.5 mg EContra One-Step ® is an OTC emergency contraceptive Other 1.5 mg levonorgestrel emergency contraceptive products which include: Plan B One-Step ® , EContra ® EZ, My Way ® , AfterPill ® , Fallback Solo ™ , Opcicon ™ One-Step, Fallback Solo ® , and Aftera ® Effective up to 3 days after unprotected sex or contraceptive failure Product Information USAGE: EContra One-Step ® (levonorgestrel 1.5 mg tablet) is a progestin-only emergency contraceptive for use in women to reduce chance of pregnancy after unprotected sex (if contraceptive failed or birth control not used). EContra One-Step ® is not intended to be used in place of routine birth control. WHO SHOULD NOT USE ECONTRA One-Step ® : Women who are known to be pregnant as it will not work. However, EContra One-Step ® will not harm an existing pregnancy. Women known to be allergic to Levonorgestrel. Women should ask a doctor or pharmacist before using EContra One-Step ® if taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of levonorgestrel. SIDE EFFECTS MAY INCLUDE: Menstrual changes Abdominal pain Nausea or vomiting Tiredness Headache Dizziness Breast pain Reference: EContra One-Step ® [product information]. Charleston, SC: Afaxys Pharma, LLC; October 2019. Please see full Product Information here . To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088. Launched March 2015 Effective up to three days after unprotected sex or contraceptive failure read more Annovera ® (segesterone acetate and ethinyl estradiol vaginal system), delivers 0.15 mg / 0.013 mg per day Afaxys is an authorized promotional partner for ANNOVERA. Annovera ® (segesterone acetate and ethinyl estradiol vaginal system), delivers 0.15 mg / 0.013 mg per day Afaxys is an authorized promotional partner for ANNOVERA. ANNOVERA is a soft and flexible, patient-controlled vaginal ring that provides contraception for 1-year (thirteen cycles) when inserted for 21 days and removed for 7 days each cycle Created with a novel hormone profile, ANNOVERA releases a non-androgenic progestin (segesterone acetate) and one of the lowest doses of ethinyl estradiol (0.013 mg) daily 1* Each box contains one ANNOVERA individually packaged in an aluminum pouch. A black compact case is provided with the drug product for storage of ANNOVERA by patients during each 7-day vaginal system-out interval *Based on pharmacological studies in animals and in vitro studies. The clinical significance of these data is not known. 1.Kumar N, Koide SS, Tsong YY, Sundaram K. Nestorone: A progestin with a unique pharmacological profile. Steroids, 2000;65:629-36. IMPORTANT SAFETY INFORMATION WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Females over 35 years old who smoke should not use ANNOVERA. Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use. CONTRAINDICATIONS ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is contraindicated and should not be used in women with a high risk of arterial or venous thrombotic diseases; current or history of breast cancer or other estrogen- or progestin-sensitive cancer; liver tumors, acute hepatitis, or severe (decompensated) cirrhosis; undiagnosed abnormal uterine bleeding; hypersensitivity to any of the components of ANNOVERA; and use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. WARNINGS AND PRECAUTIONS Stop ANNOVERA if a thrombotic or thromboembolic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Start ANNOVERA no earlier than 4 weeks after delivery, in females who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years Discontinue if jaundice occurs. Stop ANNOVERA prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir. ANNOVERA can be restarted 2 weeks following completion of this regimen. Do not prescribe ANNOVERA for females with uncontrolled hypertension or hypertension with vascular disease. Monitor blood pressure and stop use if blood pressure rises significantly in females with wellcontrolled hypertension. Monitor glucose in pre-diabetic or diabetic females taking ANNOVERA. Consider an alternate contraceptive method for females with uncontrolled dyslipidemias. Patients using ANNOVERA who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. ANNOVERA should be discontinued if indicated. Other warnings include: gallbladder disease; depression; cervical cancer; increased serum concentrations of binding globulins; hereditary angioedema; chloasma (females who tend to develop chloasma should avoid exposure to the sun or UV radiation while using ANNOVERA); toxic shock syndrome (TSS) (if a patient exhibits symptoms of TSS, remove ANNOVERA, and initiate appropriate medical treatment); vaginal use (ANNOVERA may not be suitable for females with conditions that make the vagina more susceptible to vaginal irritation or ulceration) ADVERSE REACTIONS The most common adverse reactions reported in at least 5% of women who received ANNOVERA were: headache/migraine, nausea/vomiting, vulvovaginal mycotic infection/candidiasis, lower/upper abdominal pain, dysmenorrhea, vaginal discharge, urinary tract infection, breast pain/tenderness/discomfort, bleeding irregularities including metrorrhagia, diarrhea, and genital pruritus. DRUG INTERACTIONS Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of ANNOVERA or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with ANNOVERA. INDICATION ANNOVERA is a progestin/estrogen combination hormonal contraceptive indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: ANNOVERA has not been adequately studied in females w...